National and Kapodistrian University of Athens
Μοριακή μελέτη των γονιδίων BRCA1 και BRCA2 σε Έλληνες ασθενείς με κληρονομούμενο καρκίνο μαστού και ωοθηκών
Abstract
dc:description85 Greek patients with hereditary breast and ovarian cancer were tested with the protein truncation test (PTT) for mutations in peripheral blood DNA in exon 11 of the BRCA1 gene and exons 10 and 11 of the BRCA2 gene (60% of the coding region of both genes). Totally eight deleterious mutations were detected and identified with automated DNA Sequencing: six in BRCA1 (3741insA, 1623del5, 3099delT, 3277insG, R1203X και 3896delT) and two in BRCA2 (2024del5 in exon 10 και 6631del5 in exon 11). Two of them are novel mutations reported for the first time in the literature (3099delT, 3277insG). Then, in tumor samples of 20 patients from the above group, prognostic factors of breast cancer were evaluated like ER, PgR, p53, Ki-67 and c-erbB-2 with immunohistochemistry and ploidy, DNA Index and proliferative phase with image cytometry. The tumors of five patients that tested positive for BRCA1 mutation (in peripheral blood) are negative for ER content and c-erbB-2 overexpression while in parallel they possessed intense proliferation (high Ki-67 and proliferative phase, giant cells in two). Two of the BRCA1 patients were recorded as medullary breast carcinomas in their histology report. The above reported phenotypic biological characteristics could assist in the detection of more genotypic changes in the highly penetrant BRCA1 gene. Therefore in a population-based study of patients fulfilling the aforementioned criteria, the recurrent 5382insC BRCA1 mutation was detected in one patient with PSM-PCR-RFLP methodology. Also, an immunohistochemical technique for the detection of BRCA1 protein was developed (MS110 mAb) and then applied: a) in a group of 30 sporadic breast cancer tumors where the range and intensity of positivity were recorded and b) in the 5 BRCA1 positive tumors (3 were assigned negative for BRCA1 protein). Finally, methods for the measurement of BRCA1 mRNA levels were developed: a) a semi quantitative hybridization method for PCR products and chemiluminescent detection in an ELISA microtiter plate and b) a sensitive quantitative method for BRCA1-mRNA with real time RT-PCR with the use of a Taqman DNA probe, conjugated with the fluorescent fluorescein dye and continuous monitoring in the Light Cycler instrument. This second method was applied: a) in peripheral blood samples of patients with breast cancer for the investigation of detection of circulating cancer cells where after checking healthy blood donors, positive BRCA1 signal was detected in 13/41 (32%) samples of metastatic breast cancer and b) in cultures of the MCF-7 breast cancer cell line after treatment with chemotherapeutic agents or radiation.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2003
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Kroupis, Christos
- Κρούπης, Χρήστος
Subjects
dc:subject × 21- Γονίδιο BRCA1
- Γονίδιο BRCA2
- Καρκίνος μαστού
- Καρκίνος ωοθηκών
- Ανίχνευση μεταλλάξεων
- Προγνωστικοί παράγοντες
- Ανοσοϊστοχημεία
- Μέτρηση επιπέδων mRNA1 BRCA1
- BRCA1 gene
- BRCA2 gene
- Breast cancer
- Ovarian cancer
- Mutation detection
- PTT
- Prognostic factors
- Immunohistochemistry ( IHC)
- Measurement of mRNA BRCA1 levels
- Φυσικές Επιστήμες
- Χημεία
- Natural Sciences
- Chemical Sciences
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/21483